A Phase I/II Study to Assess the Safety and Efficacy of Pazopanib and MK 3475 in Subjects With Advanced Renal Cell Carcinoma
Phase of Trial: Phase I/II
Latest Information Update: 05 Sep 2019
Price : $35 *
At a glance
- Drugs Pazopanib (Primary) ; Pembrolizumab (Primary)
- Indications Renal cell carcinoma
- Focus Adverse reactions; Therapeutic Use
- Acronyms KEYNOTE-018
- Sponsors GlaxoSmithKline; Novartis
- 26 Apr 2019 Status changed from active, no longer recruiting to completed.
- 05 Sep 2018 Planned End Date changed from 9 Feb 2019 to 17 Apr 2019.
- 05 Sep 2018 Planned primary completion date changed from 12 Aug 2018 to 17 Apr 2019.